keyword
MENU ▼
Read by QxMD icon Read
search

vedolizumab crohn's

keyword
https://www.readbyqxmd.com/read/28523450/a-review-of-the-clinical-pharmacokinetics-pharmacodynamics-and-immunogenicity-of-vedolizumab
#1
REVIEW
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede, Tim Wyant, Eric Fedyk, Irving Fox
Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), vedolizumab is administered as a 300 mg intravenous infusion. Vedolizumab undergoes a rapid, saturable, non-linear, target-mediated elimination process at low concentrations and a slower, linear, non-specific elimination process at higher concentrations...
May 18, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28509816/variations-in-health-insurance-policies-regarding-biologic-therapy-use-in-inflammatory-bowel-disease
#2
Abhijeet Yadav, Joshua Foromera, Ilana Feuerstein, Kenneth R Falchuk, Joseph D Feuerstein
BACKGROUND: The American Gastroenterological Association (AGA) has developed guidelines for the management of ulcerative colitis and Crohn's disease (CD) recommending anti-TNF therapy in moderate-severe disease. However, which drug is used is often dictated by insurance company policies. We sought to determine the insurance policy requirements prior to approval of biologic therapies. METHODS: Using the National Association of Insurance Commissioners report of the top 125 insurance companies by market share in 2014, we reviewed the first 50 that had online policies regarding anti-TNF and vedolizumab available...
June 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28509767/variations-in-health-insurance-policies-regarding-biologic-therapy-use-in-inflammatory-bowel-disease
#3
Abhijeet Yadav, Joshua Foromera, Ilana Feuerstein, Kenneth R Falchuk, Joseph D Feuerstein
BACKGROUND: The American Gastroenterological Association (AGA) has developed guidelines for the management of ulcerative colitis and Crohn's disease (CD) recommending anti-TNF therapy in moderate-severe disease. However, which drug is used is often dictated by insurance company policies. We sought to determine the insurance policy requirements prior to approval of biologic therapies. METHODS: Using the National Association of Insurance Commissioners report of the top 125 insurance companies by market share in 2014, we reviewed the first 50 that had online policies regarding anti-TNF and vedolizumab available...
May 15, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28494241/gut-microbiome-function-predicts-response-to-anti-integrin-biologic-therapy-in-inflammatory-bowel-diseases
#4
Ashwin N Ananthakrishnan, Chengwei Luo, Vijay Yajnik, Hamed Khalili, John J Garber, Betsy W Stevens, Thomas Cleland, Ramnik J Xavier
The gut microbiome plays a central role in inflammatory bowel diseases (IBDs) pathogenesis and propagation. To determine whether the gut microbiome may predict responses to IBD therapy, we conducted a prospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizumab). Disease activity and stool metagenomes at baseline, and weeks 14, 30, and 54 after therapy initiation were assessed. Community α-diversity was significantly higher, and Roseburia inulinivorans and a Burkholderiales species were more abundant at baseline among CD patients achieving week 14 remission...
May 10, 2017: Cell Host & Microbe
https://www.readbyqxmd.com/read/28469372/a-rare-case-of-crohn-s-ileitis-in-a-patient-with-constitutional-mismatch-repair-deficiency
#5
Pavlos Kaimakliotis, Francis Giardiello, Ogechukwu Eze, Brindusa Truta
Constitutional mismatch repair deficiency (CMMRD), a variant of Lynch syndrome, is a rare disease characterized by café-au-lait spots, oligopolyposis, glioblastoma and lymphoma. A 24-year-old male, under surveillance for CMMRD, developed Crohn's ileitis after total colectomy with end ileostomy for colorectal cancer and failed to respond to oral corticosteroids. The patient underwent induction and maintenance of remission with vedolizumab infusions. We report the first patient with CMMRD developing Crohn's disease...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28434387/cost-utility-of-biological-treatment-sequences-for-luminal-crohn-s-disease-in-europe
#6
Fanni Rencz, László Gulácsi, Márta Péntek, Krisztina B Gecse, Axel Dignass, Jonas Halfvarson, Fernando Gomollón, Petra Baji, Laurent Peyrin-Biroulet, Péter L Lakatos, Valentin Brodszky
OBJECTIVES: To compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn's disease in nine European countries. METHODS: A Markov-model was constructed to simulate five-year medical costs and quality-adjusted life years (QALYs). Data on clinical efficacy were obtained from randomised controlled trials. Country-specific unit costs, discount rates and a third-party payer perspective were applied...
April 24, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28369329/vedolizumab-induces-long-term-mucosal-healing-in-patients-with-crohn-s-disease-and-ulcerative-colitis
#7
Maja Noman, Marc Ferrante, Raf Bisschops, Gert De Hertogh, Karolien Van den Broeck, Karen Rans, Paul J Rutgeerts, Séverine Vermeire, Gert Van Assche
Introduction.: Vedolizumab has proven efficacy in IBD, but long term mucosal healing in Crohn's disease (CD), as well as the incidence of colorectal neoplasia in IBD, among patients treated with vedolizumab have not been studied. We aimed to document mucosal healing and to explore the risk of colorectal neoplasia with vedolizumab maintenance therapy. Methods.: Surveillance colonoscopy was prospectively scheduled for patients with longstanding UC or CD at a tertiary referral center in the open label extension phase (vedolizumab 300 mg IV q 4 wks) of the Gemini studies (GEMINI LTS, study number NCT00790933)...
March 24, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28362144/long-term-effectiveness-of-vedolizumab-in-inflammatory-bowel-disease-a-national-study-based-on-the-swedish-national-quality-registry-for-inflammatory-bowel-disease-swibreg
#8
Carl Eriksson, Jan Marsal, Daniel Bergemalm, Lina Vigren, Jan Björk, Michael Eberhardson, Pontus Karling, Charlotte Söderman, Pär Myrelid, Yang Cao, Daniel Sjöberg, Mari Thörn, Per Karlén, Erik Hertervig, Hans Strid, Jonas F Ludvigsson, Sven Almer, Jonas Halfvarson
OBJECTIVES: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness. MATERIALS AND METHODS: Patients initiating vedolizumab between 1 June 2014 and 30 May 2015 were identified through the Swedish National Quality Registry for IBD. Prospectively collected data on treatment and disease activity were extracted...
June 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28357697/predictors-of-clinical-response-and-remission-at-1%C3%A2-year-among-a-multicenter-cohort-of-patients-with-inflammatory-bowel-disease-treated-with-vedolizumab
#9
Jessica R Allegretti, Edward L Barnes, Betsey Stevens, Margaret Storm, Ashwin Ananthakrishnan, Vijay Yajnik, Joshua Korzenik
BACKGROUND: Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in phase III trials. AIMS: Our aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients. METHODS: Adult patients completing induction therapy with VDZ were eligible for this study. Clinical response and remission was assessed using the Harvey-Bradshaw Index (HBI) for CD, the Simple Clinical Colitis Activity Index for UC and physician assessment...
March 29, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28337471/intractable-pyoderma-gangrenosum-in-a-crohn-s-disease-patient-on-vedolizumab
#10
Jennifer E Yeh, William G Tsiaras
No abstract text is available yet for this article.
March 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28333288/exposure-efficacy-relationships-for-vedolizumab-induction-therapy-in-patients-with-ulcerative-colitis-or-crohn-s-disease
#11
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Huyuan Yang, Silvio Danese, Jean-Frédéric Colombel, Michael Smyth, William J Sandborn, Brian G Feagan, Walter Reinisch, Bruce E Sands, Miguel Sans, Irving Fox
Background and Aims: A positive relationship between vedolizumab trough serum concentrations and clinical outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) has been reported. Here we further explore exposure-efficacy relationships for vedolizumab induction therapy in post hoc analyses of GEMINI study data. Methods: Vedolizumab trough concentrations at Week 6 or 10 were grouped in quartiles and clinical outcome rates calculated. Exposure-efficacy relationships at Week 6 and potential baseline covariate effects were explored using logistic regression and individual predicted cumulative average concentration through Week 6 (Caverage) as exposure measure...
February 17, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28326566/systematic-review-with-meta-analysis-comparative-efficacy-of-biologics-for-induction-and-maintenance-of-mucosal-healing-in-crohn-s-disease-and-ulcerative-colitis-controlled-trials
#12
REVIEW
A Cholapranee, G S Hazlewood, G G Kaplan, L Peyrin-Biroulet, A N Ananthakrishnan
BACKGROUND: Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. AIM: To perform a systematic review and meta-analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. METHODS: We performed a systematic review and meta-analysis of randomised controlled trials (RCT) examining mucosal healing as an endpoint of immunosuppressives, anti-tumour necrosis factor α (anti-TNF) or anti-integrin monoclonal antibody therapy for moderate-to-severe CD or UC...
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28247573/review-article-moving-towards-common-therapeutic-goals-in-crohn-s-disease-and-rheumatoid-arthritis
#13
REVIEW
P B Allen, P Olivera, P Emery, D Moulin, J-Y Jouzeau, P Netter, S Danese, B Feagan, W J Sandborn, L Peyrin-Biroulet
BACKGROUND: Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability. AIM: To review the similarities and differences in treatment goals between CD and rheumatoid arthritis...
March 1, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28221249/the-%C3%AE-4%C3%AE-1-homing-pathway-is-essential-for-ileal-homing-of-crohn-s-disease-effector-t-cells-in-vivo
#14
Sebastian Zundler, Anika Fischer, Daniela Schillinger, Marie-Theres Binder, Raja Atreya, Timo Rath, Rocío Lopez-Pósadas, Caroline J Voskens, Alastair Watson, Imke Atreya, Clemens Neufert, Markus F Neurath
BACKGROUND: The precise mechanisms controlling homing of T effector (Teff) cells to the inflamed gut in Crohn's disease (CD) are still unclear, and clinical outcome data from patients with inflammatory bowel disease treated with the anti-α4β7 integrin antibody vedolizumab suggest differences between ulcerative colitis and CD. METHODS: Expression of homing molecules was studied with flow cytometry and immunohistochemistry. Their functional role was investigated in in vitro adhesion assays and in a humanized mouse model of T cell homing to the inflamed gut in vivo...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28204866/vedolizumab-treatment-for-immune-checkpoint-inhibitor-induced-enterocolitis
#15
Viktoria Bergqvist, Erik Hertervig, Peter Gedeon, Marija Kopljar, Håkan Griph, Sara Kinhult, Ana Carneiro, Jan Marsal
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selective activation of the immune system, immune-related adverse events (irAEs) are frequent. Enterocolitis is a common irAE, currently managed with corticosteroids and, if necessary, anti-tumor necrosis factor-α therapy...
May 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28178003/efficacy-and-safety-of-vedolizumab-for-induction-of-remission-in-inflammatory-bowel-disease-the-israeli-real-world-experience
#16
Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar-Gil Shitrit, Eran Israeli, Doron Schwartz, Eran Zittan, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan
BACKGROUND: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the "real world" efficacy and safety of VDZ in a large national patient cohort. METHODS: Patients with inflammatory bowel disease treated with VDZ were prospectively followed for 14 weeks. Patients who completed the induction protocol (week 0/2/6/14) or discontinued the treatment before week 14 for adverse events (AEs) or primary nonresponse were included...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28175096/p445-perioperative-use-of-vedolizumab-seems-not-associated-with-short-term-postoperative-infectious-complications-in-patients-with-crohn-s-disease-undergoing-right-hemicolectomy-with-ileocolonic-anastomosis
#17
N Schils, A De Buck van Overstraeten, S Vermeire, G Van Assche, A Wolthuis, A D'Hoore, M Ferrante
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175093/p501-baseline-characteristics-of-crohn-s-disease-patients-in-the-vedolizumab-pass-study-a-cohort-study-assessing-the-safety-and-effectiveness-of-vedolizumab-compared-to-other-biologic-agents-02
#18
C A Siegel, G Lichtenstein, B Siegmund, J D Lewis, D Wolf, E Louis, S Sebastian, X Hebuterne, A Bell, C Söderman, S Schubert, R Atreya, S Polyak, S Hoque, A Krummenerl, B Bokemeyer, T Krummenerl, S Shulmann, P Karlén, B Moum, P Dolin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172955/p447-vedolizumab-induces-significantly-higher-endoscopic-remission-rates-at-week-16-in-ulcerative-colitis-as-compared-to-crohn-s-disease
#19
R W M Pauwels, A C De Vries, C J Van der Woude
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172925/p391-differential-use-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-real-life-results-from-2-tertiary-referral-centres-in-the-united-kingdom
#20
N Kamperidis, A Cavazza, M Wahed, N Arebi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
keyword
keyword
45192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"